• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

双齿丙二酸酯配体对L1210细胞系中铂化合物利用及细胞毒性的影响。

Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.

作者信息

Mauldin S K, Husain I, Sancar A, Chaney S G

出版信息

Cancer Res. 1986 Jun;46(6):2876-82.

PMID:3698013
Abstract

Previous studies have investigated the cytotoxicity of platinum(II) compounds with bidentate leaving ligands, but little is known about their uptake or mechanism of action inside the cell. We have compared the uptake and intracellular effects of cis-1,2-diaminocyclohexanemalonatoplatinum(II) [Pt(mal)(cis-DACH)] and cis-1,2-diaminocyclohexanedichloroplatinum(II) [PtCl2(cis-DACH)] in the L1210 cell line. In the 3-h colony formation assay, PtCl2(cis-DACH) is almost 10 times more cytotoxic than Pt(mal)(cis-DACH). However, when the time of incubation with platinum drug is increased from 3 to 24 h the cytotoxicity of PtCl2(cis-DACH) changes relatively little while the cytotoxicity of Pt(mal)(cis-DACH) increases over 10-fold. As a consequence, Pt(mal)(cis-DACH) is only slightly less cytotoxic than the dichloro compound by 24 h. These data can readily be explained by differences in the time course of uptake. Pt(mal)(cis-DACH) is initially taken by the cell at a much slower rate than PtCl2(cis-DACH), but the uptake continues linearly for at least 24 h with the malonate compound, while uptake for the dichloro compound begins to plateau between 5 and 8 h. The earlier plateauing of PtCl2(cis-DACH) uptake is most likely to be due to a quicker approach to equilibrium between intracellular and extracellular concentrations of unchanged drug which is caused by a more rapid inactivation of PtCl2(cis-DACH) in the media coupled with the more rapid uptake of PtCl2(cis-DACH) by the cells. When compared at equal cytotoxicity, the uptake of platinum into the intracellular pool of low molecular weight platinum compounds is significantly greater for Pt(mal)(cis-DACH) even though the rate of platinum incorporation into DNA is essentially the same for both compounds at early times. These data suggest that a smaller percentage of the low molecular weight platinum is in a reactive form inside the cell for Pt(mal)(cis-DACH). While the inhibition of cell survival exactly parallels incorporation of platinum into DNA for both compounds, there is a significant lag before the onset of inhibition of DNA synthesis for Pt(mal)(cis-DACH). This observation suggests that the conversion of monoadducts to diadducts may be slower for platinum compounds with bidentate leaving ligands.

摘要

以往的研究调查了带有双齿离去配体的铂(II)化合物的细胞毒性,但对于它们在细胞内的摄取情况或作用机制却知之甚少。我们比较了顺式-1,2-二氨基环己烷丙二酸铂(II)[Pt(mal)(cis-DACH)]和顺式-1,2-二氨基环己烷二氯铂(II)[PtCl2(cis-DACH)]在L1210细胞系中的摄取情况和细胞内效应。在3小时集落形成试验中,PtCl2(cis-DACH)的细胞毒性几乎是Pt(mal)(cis-DACH)的10倍。然而,当铂药物的孵育时间从3小时增加到24小时时,PtCl2(cis-DACH)的细胞毒性变化相对较小,而Pt(mal)(cis-DACH)的细胞毒性增加了10倍以上。因此,到24小时时,Pt(mal)(cis-DACH)的细胞毒性仅比二氯化合物略低。这些数据很容易用摄取时间进程的差异来解释。Pt(mal)(cis-DACH)最初被细胞摄取的速度比PtCl2(cis-DACH)慢得多,但丙二酸化合物的摄取至少持续24小时呈线性,而二氯化合物的摄取在5到8小时之间开始趋于平稳。PtCl2(cis-DACH)摄取较早趋于平稳很可能是由于细胞内和细胞外未变化药物浓度之间更快地达到平衡,这是由培养基中PtCl2(cis-DACH)更快地失活以及细胞对PtCl2(cis-DACH)更快地摄取所导致的。当在同等细胞毒性下进行比较时,即使在早期两种化合物将铂掺入DNA的速率基本相同时,Pt(mal)(cis-DACH)进入低分子量铂化合物细胞内池的铂摄取量也显著更高。这些数据表明,对于Pt(mal)(cis-DACH),细胞内低分子量铂中以反应性形式存在的比例较小。虽然两种化合物对细胞存活的抑制与铂掺入DNA的情况完全平行,但对于Pt(mal)(cis-DACH),在DNA合成抑制开始之前有一个明显的延迟。这一观察结果表明,对于带有双齿离去配体的铂化合物,单加合物向双加合物的转化可能较慢。

相似文献

1
Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.双齿丙二酸酯配体对L1210细胞系中铂化合物利用及细胞毒性的影响。
Cancer Res. 1986 Jun;46(6):2876-82.
2
Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.L1210细胞系中铂化合物与1,2 - 二氨基环己烷载体配体的细胞内生物转化
Cancer Res. 1988 Sep 15;48(18):5136-44.
3
Role of carrier ligand in platinum resistance in L1210 cells.载体配体在L1210细胞铂耐药中的作用。
Cancer Res. 1990 Oct 15;50(20):6497-501.
4
Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.轴向和赤道配体介导的1,2-二氨基环己烷铂(IV)配合物的细胞毒性和细胞药理学调节
Cancer Res. 1993 Oct 1;53(19):4567-72.
5
Role of carrier ligand in platinum resistance of human carcinoma cell lines.载体配体在人癌细胞系铂耐药中的作用。
Cancer Res. 1993 Feb 15;53(4):799-805.
6
Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).轴向配体和脂环大小调节氨/环烷基胺-铂(IV)配合物在对顺二氯二氨铂(II)或反式-1R,2R-1S,2S-二氨基环己烷四氯铂(IV)耐药的肿瘤细胞中的活性和生化药理学。
Cancer Res. 1994 Sep 1;54(17):4691-7.
7
Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.轴向和赤道配体对反式-1R,2R-二氨基环己烷铂(IV)配合物抗肿瘤活性的调节作用。
Anticancer Drug Des. 1994 Apr;9(2):139-51.
8
An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.四氯-(d,l-反式)-1,2-二氨基环己烷铂(IV)(四铂)在L1210细胞系中的一条意外生物转化途径。
Cancer Res. 1991 Feb 1;51(3):969-73.
9
Inhibition of nucleic acid synthesis in P388 lymphocytic leukemia cells in culture by cis-platinum derivatives.
Biomed Biochim Acta. 1990;49(7):579-87.
10
Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.DNA复制在L1210细胞对铂化合物的载体-配体特异性抗性中的作用。
Carcinogenesis. 1991 Dec;12(12):2253-7. doi: 10.1093/carcin/12.12.2253.

引用本文的文献

1
Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.奥马铂的药代动力学和生物转化研究以及一项I期临床试验
Cancer Chemother Pharmacol. 1994;33(4):347-54. doi: 10.1007/BF00685911.